医药：I类新药培泰菁绿完成I期临床验证，助力术中精准诊断

Investment Rating - The report indicates a positive outlook for the investment in the molecular imaging industry, particularly focusing on the innovative drug Peitaiqing Green developed by Nanjing Nuoyuan Medical Equipment Co., Ltd. [1] Core Insights - Peitaiqing Green has successfully completed Phase I clinical trials in China, demonstrating excellent safety and pharmacokinetic characteristics, positioning it as a promising tool for precise intraoperative tumor diagnosis [1][9] - The drug targets folate receptor alpha (FRα), which is overexpressed in various malignancies, making it an ideal biomarker for tumor diagnosis and treatment [4] - The report highlights the strategic dual-track clinical development plan for Peitaiqing Green in both domestic and international markets, emphasizing its potential for global commercialization [16][18] Summary by Sections 1. Clinical Application Value of Peitaiqing Green - FRα is a key tumor biomarker, showing overexpression in cancers like lung and ovarian cancer, which supports the development of targeted imaging agents [4] - Peitaiqing Green exhibits high selectivity for FRα, significantly improving tumor imaging accuracy and reducing false positive rates [5][14] 2. Clinical Trial Results - The Phase I clinical trial in China included 32 healthy subjects, with no drug-related adverse events reported, indicating good safety [9][10][13] - Pharmacokinetic data showed a linear increase in AUC and Cmax with dosage, with a half-life ranging from 1.59 to 7.86 hours, suggesting predictable metabolism [11][15] 3. Global Clinical Development and Market Strategy - Nanjing Nuoyuan has established a dual-track clinical development strategy for Peitaiqing Green, with patent protections in multiple countries, enhancing its global market potential [16][18] - The company is preparing for clinical trials in the U.S. following FDA IND approval, aiming to position Peitaiqing Green as a leading targeted imaging agent [18] 4. Product Pipeline and Strategic Layout - Nanjing Nuoyuan has a robust pipeline of molecular imaging products, including the next-generation broad-spectrum fluorescent agent Gandoqing Green and the SPECT-CT radiopharmaceutical NY-99mTc-FAPI-068, indicating strong innovation capabilities [19] - The company integrates high-end medical devices with innovative targeted imaging agents, focusing on providing comprehensive solutions for tumor precision diagnosis [20][21]